AndhraNews.net
Home » Business News » 2014 » May » May 21, 2014

Hepregen Launches First Rat Hepatopac(TM) Assay Kit to Evaluate Hepatotoxicity in the Laboratory


May 21, 2014 - West Conshohocken, PA

WEST CONSHOHOCKEN, PA--(Marketwired - May 21, 2014) - Today at its first annual Mid-Atlantic User Group Meeting Hepregen Corporation, a leader in the development of next generation HepatoPac™ and HepatoMune™ cell-based in vitro assay products, announced the commercial launch of the company's first rat HepatoPac™ kit designed specifically for toxicology applications. The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned rat liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates mirror the behavior of liver cells in live animals, enabling scientists to generate data that can be useful for prediction of toxic responses to chemical agents (including drug candidates) and improve design of preclinical experiments for drug development. The application-directed kit also provides a tool for the study of the mechanisms leading to such responses.

The kit is available with rat liver cells derived from either Sprague-Dawley or Wistar-Han rats, two strains of animal commonly used by pharmaceutical, cosmetic and chemical companies for assessing the potential toxicity of chemical compounds in product development.

Dr. Vincent Zurawski, Hepregen's Chief Executive Officer, stated, "This new kit is the second HepatoPac™ application-directed kit that is focused on the in vitro toxicology market. The first, a human HepatoPac™ kit, was introduced in March of this year. Now, scientists can compare test results using human and rat cells, which enables a more informed approach to the design of preclinical toxicology studies of drug candidates, and an ability to make better decisions about advancement of chemical agent product development programs in the cosmetics and chemical industries." 

About Hepregen Corporation

Hepregen Corporation is a leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and product development in the pharmaceutical and biopharmaceutical, diagnostic, cosmetics, and chemical industries. The company's micro-liver HepatoPac™ and HepatoMune™ cell-based assays are intended to drive a paradigm shift in drug development. The utility of Hepregen's human, rat, monkey, dog, and multi-species/multi-donor HepatoPac™ and HepatoMune™ application-directed products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Ventures and Innovation Valley Partners with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements. Such forward-looking statements reflect Hepregen Corporation's expectations about its future operating results, performance and opportunities that involve substantial risk and uncertainties. These statements include but are not limited to statements regarding the performance and results of the company's HepatoPac™ application-directed kits. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target," "intend" and "expect" and similar expressions, as they relate to Hepregen Corporation or its management are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to Hepregen Corporation and are subject to a number of risks, uncertainties and other factors that could cause Hepregen Corporation's actual results, performance, prospects and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Image Available: http://www.marketwire.com/library/MwGo/2014/5/21/11G016003/Images/Rat_Tox_slider2-904738925703.jpg

Media Contacts

Hepregen Corporation 
Katherine Sydney Cook 
Tel: 1-781-391-0205 
Email: ksydneycook@hepregen.com  
www.hepregen.com

MarketWire

Comment on this story

Share